Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 136.96 Billion KRW | 20.98% |
| 2022 | 113.21 Billion KRW | 26.91% |
| 2021 | 89.2 Billion KRW | 21.1% |
| 2020 | 73.66 Billion KRW | -13.02% |
| 2019 | 84.69 Billion KRW | 0.22% |
| 2018 | 84.5 Billion KRW | 0.37% |
| 2017 | 84.19 Billion KRW | -9.65% |
| 2016 | 93.18 Billion KRW | -0.09% |
| 2015 | 93.27 Billion KRW | 19.3% |
| 2014 | 78.17 Billion KRW | 16.88% |
| 2013 | 66.88 Billion KRW | -5.63% |
| 2012 | 70.88 Billion KRW | 4.38% |
| 2011 | 67.9 Billion KRW | 16.79% |
| 2010 | 58.14 Billion KRW | -23.95% |
| 2009 | 76.45 Billion KRW | 10.01% |
| 2008 | 69.49 Billion KRW | 14.0% |
| 2007 | 60.96 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 143.31 Billion KRW | 2.31% |
| 2024 Q1 | 140.07 Billion KRW | 2.26% |
| 2023 Q1 | 117.58 Billion KRW | 3.86% |
| 2023 Q3 | 132.65 Billion KRW | 8.46% |
| 2023 Q2 | 122.3 Billion KRW | 4.02% |
| 2023 FY | 136.96 Billion KRW | 20.98% |
| 2023 Q4 | 136.96 Billion KRW | 3.25% |
| 2022 Q1 | 99.74 Billion KRW | 11.81% |
| 2022 Q2 | 101.96 Billion KRW | 2.22% |
| 2022 Q3 | 103.98 Billion KRW | 1.98% |
| 2022 Q4 | 113.21 Billion KRW | 8.88% |
| 2022 FY | 113.21 Billion KRW | 26.91% |
| 2021 FY | 89.2 Billion KRW | 21.1% |
| 2021 Q1 | 79.45 Billion KRW | 7.86% |
| 2021 Q2 | 81.81 Billion KRW | 2.96% |
| 2021 Q3 | 80.47 Billion KRW | -1.63% |
| 2021 Q4 | 89.2 Billion KRW | 10.85% |
| 2020 Q3 | 82.29 Billion KRW | -1.91% |
| 2020 Q2 | 83.9 Billion KRW | -1.48% |
| 2020 Q1 | 85.16 Billion KRW | 0.55% |
| 2020 FY | 73.66 Billion KRW | -13.02% |
| 2020 Q4 | 73.66 Billion KRW | -10.48% |
| 2019 Q2 | 93.8 Billion KRW | 5.99% |
| 2019 Q3 | 77.3 Billion KRW | -17.59% |
| 2019 Q4 | 84.69 Billion KRW | 9.56% |
| 2019 FY | 84.69 Billion KRW | 0.22% |
| 2019 Q1 | 88.5 Billion KRW | 4.73% |
| 2018 Q2 | 78.02 Billion KRW | -1.99% |
| 2018 Q4 | 84.5 Billion KRW | 1.28% |
| 2018 FY | 84.5 Billion KRW | 0.37% |
| 2018 Q1 | 79.6 Billion KRW | -5.45% |
| 2018 Q3 | 83.44 Billion KRW | 6.95% |
| 2017 Q3 | 86.39 Billion KRW | -5.85% |
| 2017 Q4 | 84.19 Billion KRW | -2.54% |
| 2017 FY | 84.19 Billion KRW | -9.65% |
| 2017 Q1 | 89.43 Billion KRW | -4.03% |
| 2017 Q2 | 91.76 Billion KRW | 2.61% |
| 2016 Q4 | 93.18 Billion KRW | -0.58% |
| 2016 FY | 93.18 Billion KRW | -0.09% |
| 2016 Q3 | 93.72 Billion KRW | 3.71% |
| 2016 Q2 | 90.37 Billion KRW | -0.82% |
| 2016 Q1 | 91.11 Billion KRW | -2.31% |
| 2015 Q2 | 86.2 Billion KRW | 6.77% |
| 2015 Q4 | 93.27 Billion KRW | 5.71% |
| 2015 Q3 | 88.23 Billion KRW | 2.35% |
| 2015 Q1 | 80.74 Billion KRW | 3.28% |
| 2015 FY | 93.27 Billion KRW | 19.3% |
| 2014 Q1 | 63.9 Billion KRW | -4.46% |
| 2014 Q2 | 63.37 Billion KRW | -0.83% |
| 2014 FY | 78.17 Billion KRW | 16.88% |
| 2014 Q4 | 78.17 Billion KRW | 11.87% |
| 2014 Q3 | 69.88 Billion KRW | 10.27% |
| 2013 Q3 | 76.08 Billion KRW | -0.2% |
| 2013 Q4 | 66.88 Billion KRW | -12.09% |
| 2013 Q2 | 76.23 Billion KRW | 5.73% |
| 2013 FY | 66.88 Billion KRW | -5.63% |
| 2013 Q1 | 72.1 Billion KRW | 1.73% |
| 2012 FY | 70.88 Billion KRW | 4.38% |
| 2012 Q4 | 70.88 Billion KRW | -3.06% |
| 2012 Q3 | 73.12 Billion KRW | 7.63% |
| 2012 Q2 | 67.93 Billion KRW | 0.21% |
| 2012 Q1 | 67.79 Billion KRW | -0.16% |
| 2011 FY | 67.9 Billion KRW | 16.79% |
| 2011 Q2 | 54.04 Billion KRW | 3.01% |
| 2011 Q1 | 52.46 Billion KRW | -9.77% |
| 2011 Q4 | 67.9 Billion KRW | 24.54% |
| 2011 Q3 | 54.52 Billion KRW | 0.89% |
| 2010 Q1 | 80.82 Billion KRW | 5.71% |
| 2010 Q4 | 58.14 Billion KRW | -2.97% |
| 2010 Q3 | 59.92 Billion KRW | -21.24% |
| 2010 Q2 | 76.09 Billion KRW | -5.85% |
| 2010 FY | 58.14 Billion KRW | -23.95% |
| 2009 Q1 | 77 Billion KRW | 10.81% |
| 2009 Q4 | 76.45 Billion KRW | 4.63% |
| 2009 FY | 76.45 Billion KRW | 10.01% |
| 2009 Q2 | 73.5 Billion KRW | -4.55% |
| 2009 Q3 | 73.07 Billion KRW | -0.59% |
| 2008 Q2 | 60.73 Billion KRW | -0.91% |
| 2008 Q4 | 69.49 Billion KRW | 14.57% |
| 2008 FY | 69.49 Billion KRW | 14.0% |
| 2008 Q3 | 60.65 Billion KRW | -0.12% |
| 2008 Q1 | 61.29 Billion KRW | 0.54% |
| 2007 Q1 | 110.5 Billion KRW | 0.0% |
| 2007 Q4 | 60.96 Billion KRW | -38.26% |
| 2007 Q3 | 98.73 Billion KRW | -2.4% |
| 2007 Q2 | 101.15 Billion KRW | -8.46% |
| 2007 FY | 60.96 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -75.921% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 85.269% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 80.629% |
| HANDOK Inc. | 449.7 Billion KRW | 69.543% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -59.879% |
| Yuhan Corporation | 712.33 Billion KRW | 80.772% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 78.325% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -761.736% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 83.921% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -155.879% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 33.47% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -82.209% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 7.325% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -94.554% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -75.921% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -275.913% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 45.464% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 37.941% |
| JW Holdings Corporation | 827.51 Billion KRW | 83.448% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 68.657% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 76.658% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 63.918% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -72.719% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -95.76% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 43.6% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 58.531% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -75.921% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 72.048% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 84.037% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 63.918% |
| Yuhan Corporation | 712.33 Billion KRW | 80.772% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 71.334% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 73.49% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 63.918% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 11.368% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -52.246% |
| CKD Bio Corp. | 170.76 Billion KRW | 19.789% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 43.804% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 13.122% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -218.39% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -72.719% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 78.346% |
| Boryung Corporation | 373.1 Billion KRW | 63.29% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 34.212% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 33.47% |
| JW Lifescience Corporation | 96.44 Billion KRW | -42.02% |